Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Megan Blue"'
Autor:
Girish Dhall, Joseph Stanek, Megan Blue, Parth Patel, Diana Thomas, Christopher Pierson, Benita Tamrazi, Kris M Mahadeo, Jessica Fleming, Erica Bell, Katherine Miller, Olivia Grischow, Thomas Liszkay, Scott Coven, Caroline Hastings, Karen Tsui, Claire Mazewski, Gregory Friedman, Christopher Moertel, Derek Hanson, Carl Koschmann, Guy Brock, Kenneth Wong, Arnab Chakravarti, Shahab Asgharzadeh, Marvin N Nelson, Daniel Boue, Jaclyn Biegel, Elaine Mardis, Jonathan Finlay
Publikováno v:
Neuro-Oncology. 24:i192-i192
Advances in RNA and DNA profiling have identified four core molecular subgroups of medulloblastoma of prognostic significance: Sonic Hedgehog (SHH) subtype, WNT subtype, Group 3, and Group 4. Infants and young children with SHH medulloblastoma have d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::498701386341567654bb8216cd3c909c
https://doi.org/10.1093/neuonc/noac079.717
https://doi.org/10.1093/neuonc/noac079.717
Autor:
Megan Blue, Jonathan L. Finlay, Ossama M. Maher, Girish Dhall, Myeshia Harmon, Ziad Khatib, Parth Patel
Publikováno v:
Neuro-Oncology
Metabolism of drugs in infants and young children is significantly different from older individuals due to differences in distribution, protein-binding capacity, hepatic metabolism and renal excretion. To be consistent with Children’s Oncology Grou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::464d660650136df7c95e85fc4ec08034
https://doi.org/10.1093/neuonc/noaa222.037
https://doi.org/10.1093/neuonc/noaa222.037
Autor:
Pierre Giglio, Girish Dhall, Diana S Osorio, Sharon Gardner, Allison Y Liu, Kenneth E. Wong, Vinay K. Puduvalli, Daniel M. Prevedello, Megan Blue, Jonathan L. Finlay, Jeffrey C. Allen, Margaret Shatara, Joseph Stanek, Mohamed S. AbdelBaki
Publikováno v:
Neuro-Oncology
BACKGROUND We report the responses, toxicities and long-term outcomes of gemcitabine, paclitaxel and oxaliplatin (GemPOx) regimen administered, in responsive patients, prior to single cycle marrow-ablative chemotherapy (thiotepa, etoposide and carbop
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9276da940c2756388c06eed8753de979
https://doi.org/10.1093/neuonc/noaa222.283
https://doi.org/10.1093/neuonc/noaa222.283
Autor:
Isabel Almiraz-Suarez, Parth Patel, Girish Dhall, Megan Blue, Jaclyn A. Biegel, Christopher R. Pierson, Daniel R. Boue, Eugene Hwang, Jonathan L. Finlay
Publikováno v:
Neuro-Oncology
“Head Start” 4 (HS 4) is a prospective randomized clinical trial that tailors treatment based on medulloblastoma molecular subgroups and response to induction chemotherapy to compare the efficacy of one versus three (tandem) cycles of myeloablati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1da84a3b0f304b33521b7d49c9fe7d28
https://doi.org/10.1093/neuonc/noab090.026
https://doi.org/10.1093/neuonc/noab090.026